ArriVent BioPharma: doses 1st patient in U.S. phase 1 trial

What happened

• The filing says that on Oct 12, 2026 ArriVent BioPharma issued a press release announcing that the Company dosed its 1st patient in the Phase 1 trial in the U.S. with ARR-002, a potential first-in-class MUC16/NaPi2b dual-target tetravalent antibody-drug conjugate for ovarian and endometrial cancer.

Key details

• Item reported: Item 7.01, regulation FD disclosure; Item 8.01, other events.
• Drug: ARR-002 described as a MUC16/NaPi2b dual-target tetravalent antibody-drug conjugate.
• Trial: Phase 1 trial in the U.S.; 1st patient dosed reported in the Oct 12, 2026 press release.
• The press release is filed as Exhibit 99.1 and is incorporated by reference into the filing.

Why it may matter

• The filing reports Item 7.01, regulation FD disclosure, which covers public disclosure via the Oct 12, 2026 press release, and Item 8.01, other events, which references the same press release. This filing does not explain why the insider traded or why the company acted.